GlassScriptPhysician profile
Luis J Pena-Hernandez
NPI 1457562159
$163,521.76
in general payments reported to CMS, 2019-2025
36 companies · $9,981 in 2025
The $9,981 reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $12K · 2021: $13K · 2022: $4,557 · 2023: $77K · 2024: $46K · 2025: $9,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Food and Beverage: $11K · Education: $4,566 · Travel and Lodging: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $115,050.00 |
| Food and Beverage | $10,826.70 |
| Education | $4,565.78 |
| Travel and Lodging | $2,549.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $147,375.96 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $5,457.48 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,541.04 | 2020-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,159.22 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Inogen, INC. | $961.16 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| United Therapeutics Corporation | $933.75 | 2021-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $704.50 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Genzyme Corporation | $607.12 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $577.67 | 2022-2025 | Glassia |
| Grifols USA, LLC | $533.02 | 2019-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $428.04 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $342.84 | 2019-2024 | Yupelri |
| Insmed, INC. | $310.43 | 2019-2025 | Arikayce, Brinsupri |
| Sanofi-Aventis U.S. LLC | $279.97 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $272.61 | 2023-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $236.43 | 2022-2025 | Acthar |
| Verona Pharma, INC. | $211.81 | 2025 | Ohtuvayre |
| Amgen INC. | $96.93 | 2023-2024 | Tezspire |
| Vifor Pharma, INC. | $61.25 | 2024-2025 | Zemaira |
| Horizon Therapeutics Plc | $54.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.31 | 2025 | |
| Harmony Biosciences LLC | $45.19 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $43.04 | 2020 | |
| Resmed Corp | $29.98 | 2023 | |
| Axsome Therapeutics, INC. | $25.07 | 2024 | Sunosi |
| Jazz Pharmaceuticals INC. | $24.82 | 2023 | |
| Abbvie INC. | $23.47 | 2024 | |
| Lilly USA, LLC | $20.45 | 2025 | Zepbound |
| Optinose US, INC. | $19.27 | 2019 | |
| Electromed, INC. | $18.00 | 2025 | Smartvest |
| Apria Healthcare LLC | $17.27 | 2021 | |
| Inspire Medical Systems, INC. | $17.08 | 2024 | Inspire |
| Ethicon INC. | $16.87 | 2020 | |
| Merck Sharp & Dohme LLC | $15.06 | 2021 | |
| Philips North America LLC | $13.19 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Pena-Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.